Newron Pharmaceuticals S.p.a.

Farmitalia Carlo Erba S.r.l.

Farmitalia Carlo Erba

Pharmacia & Upjohn

Pharmacia Corporation

Vicuron Pharmaceuticals Inc.

Patricia Salvati

Carla Caccia

Florian Thaler

Luca Benatti

Mario Varasi

Paolo Cozzi

Elena Barbanti

Aldemio Temperilli

Ruggero Fariello

Laura Faravelli

Paolo Pevarello

Alessandra Restivo

Cibele Maria Sabido David

Corrado Ferti

Luigi Bernardi

Antonio Pillan

Orietta Veneroni

Carlo Cattaneo

Piero Melloni

Mauro Napoletano

Sergio Mantegani

Emanuela Izzo

Cibele Sabido-David

Franco Heidempergher

Daniela Ruggieri

Roberto Maj

Ermanno Moriggi

Germano Carganico

Arsenia Rossi

Claes Post

Gabriella Traquandi

Raffaella Amici

Luca Francesco Raveglia

Enzo Brambilla

Germano Bosisio

Renato Canevotti

Francesco Velardi

Francesco Ponzini

Rosanna Eccel

Sara Maestroni

Maurizio Pulici

Angelo D Volpi

Claudia Besana

Luigi Bogogna

Tiziano Ruffilli

Fariello Ruggero

Roberto Pellicciari

Enrico Di Salle

Antonio Giordani

Maria Menichincheri

Enrico Selva

Alessandro Rossi

Stefania Gagliardi

Giuliana Arcari

Alberto Bonsignori

Elena Colombo

Laura Chiodini

Daniele Losi

Anna M Caravaggi

Osvaldo Sapini

Luciano Dho

Stefano Rossetti

Laura Girola

Petra Karin Kaltofen

Marcello Calabresi

Mariia Menichincheri

Marla Menichincheri

Stefania Vallese

Roberto Forlani

Stefania Nikem Vallese

Claudia c/o Newron Pharmaceuticals SpA Besana

Florian c/o Newron Pharmaceuticals SpA Thaler

New uses of safinamide, safinamide derivatives and MAO-B inhibitors in novel types of treatment for Parkinson's Disease are described. More specifically, the invention relates to methods for treating Parkinson's Disease through the administration of safinamide, a safinamide derivative, or a MAO-B inhibitor, in combination with other Parkinson's Disease agents or treatments, such as levodopa/PDI or dopamine agonists.

Methods for treatment of Parkinson's disease

A process for obtaining therapeutically active 2-[4-(3- and 2-(fluorobenzyloxy)benzylamino]propanamides, and their salts with pharmaceutically acceptable acids with high purity degree, in particular, with a content of dibenzyl derivatives impurities lower than 0.03%, preferably lower than 0.01% by weight. The process is carried out by submitting the Schiff bases intermediates 2-[4-(3- and 2-fluorobenzyloxy)benzylideneamino]propanamides to a reduction reaction with a reducing agent selected from sodium borohydride and potassium borohydride in an appropriate amount of an organic solvent selected from C-Clower alkanols, allowing the formation and presence during a substantial position of the reduction reaction course of a suspension of the Schiff base into the saturated solution of the Schiff base into the same organic solvent.

High purity 2-[4-(3- or 2-fluorobenzyloxy)benzylamino] propanamides and methods of use thereof

The present invention is in the field of pharmacotherapy of cognitive deficits in learning and memory by administering an &#x3b1;-aminoamide, particularly safinamide. Examples of disturbances in cognition that can be treated with compounds of the invention are the ones associated with disorders such as autism, dyslexia, attention deficit hyperactivity disorder, schizophrenia, obsessive compulsive disorders, psychosis, bipolar disorders, depression, Tourette's syndrome, Mild Cognitive Impairment (MCI) and disorders of learning in children, adolescents and adults, Age Associated Memory Impairment, Age Associated Cognitive Decline, Alzheimer's Disease, Parkinson's Disease, Down's Syndrome, traumatic brain injury Huntington's Disease, Progressive Supranuclear Palsy (PSP), HIV, stroke, vascular diseases, Pick's or Creutzfeldt-Jacob diseases, multiple sclerosis (MS), other white matter disorders and drug-induced cognitive worsening.

Alpha-aminoamide derivatives useful in the treatment of cognitive disorders

There is disclosed a pharmaceutical composition comprising gabapentin or an analogue thereof (pregabalin or tiagabine) and an &#x3b1;-aminoamide and its analgesic use. A synergistic effect of the respective analgesic activities without concomitant increase of side effects was observed.

Pharmaceutical composition comprising gabapentin or an analogue thereof and an &#x3b1;-aminoamide and its analgesic use

Methods of using certain &#x3b1;-aminoamide derivatives in the treatment of RLS and addictive disorders, The compounds of this invention are able to reduce or even stop the symptoms of RLS and addictive disorders substantially without side effects.

Alpha-aminoamide derivatives useful in the treatment of addictive disorders

A process for obtaining therapeutically active 2-[4-(3- and 2-(fluorobenzyloxy)benzylamino]-propanamides and their salts with pharmaceutically acceptable acids with a high degree of purity, i.e. with a content of dibenzyl derivatives impurities lower than 0.03% by weight. The process is carried out by submitting a Schiff base intermediate to a reduction reaction with a reducing agent in an amount of organic solvent to allow the formation (and presence during a substantial portion of the reduction reaction) of a suspension of the Schiff base.

High purity 2-[4-(3- OR 2-fluorobenzyloxy)benzylamino]propanamides and methods of use thereof

2-Phenylethylamino substituted carboxamide derivatives and their use as sodium and/or calcium channel modulators useful in preventing, alleviating and curing a wide range of pathologies are presented.

2-phenylethylamino derivatives as calcium and/or sodium channel modulators

The invention relates to the use of certain alpha-aminoamide derivatives in the treatment of RLS and addictive disorders. The compounds of this invention are able to reduce or even stop the symptoms of RLS and addictive disorders substantially without side effects.

&#x3b1;-Aminoamide derivatives useful in the treatment of restless legs syndrome

The disclosure relates to pharmacotherapy of a psychiatric disorder which is schizophrenia and/or anxiety, wherein schizophrenia includes schizophrenia related disorders such as brief psychotic disorders, delusional disorders, schizoaffective disorders, and schizophreniform disorders, and anxiety includes panic disorders, obsessive-compulsive disorders (OCD), post-traumatic stress disorders (PTSD), social phobia or social anxiety disorders, specific phobia, and generalized anxiety disorders (GAD). The compounds of the disclosure are useful for the treatment of the above psychiatric disorders alone or in combination with other therapeutical agents effective in the treatment of schizophrenia and/or anxiety disorders.

Alpha-aminoamide derivatives useful in the treatment of psychiatric disorders

Methods for treatment of parkinson's disease

A process for obtaining therapeutically active 2-[4-(3- and 2-(fluorobenzyloxy)benzylamino]propanamides and their salts with pharmaceutically acceptable acids with high purity degree, in particular, with a content of dibenzyl derivatives impurities lower than 0.03%, preferably lower than 0.01% by weight. The process is carried out by submitting the Schiff bases intermediates 2-[4-(3- and 2-fluorobenzyloxy)benzylideneamino]propanamides to catalytic hydrogenation in the presence of a heterogeneous catalyst in a protic organic solvent.

Process for the production of 2-[4-(3- and 2-fluorobenzyloxy) benzylamino] propanamides

Growing community of inventors

Arese, Italy

Patricia Salvati